We’re back with another TDR Psychedelic Exclusive. In this latest, we connect again with the CEO of Numinus Wellness (TSX: NUMI), Payton Nyquvest. In case you missed it, he was last on our show at the end of May, discussing some of the initiatives planned to help better position Numinus. This time, Nyquvest is here to discuss their latest news involving a partnership between Numinus and MAPS.
The upcoming MAPS conference about to take place in Denver is generating a lot of interesting news and rumors. Many companies in the psychedelics industry will be participating, and Numinus will be one of them. Nyquvest shares what is going to be Numinus’ main objectives during the conference, and what they hope to achieve with the many practitioners who will be attending.
Visitors and investors can anticipate a range of exciting events and discussions at the MAPS conference, but what is Numinus anticipating? Nyquvest shares some thoughts, and why he believes psychedelics saved his life.
Delving into the partnership between Numinus Wellness and MAPS, Nyquvest explains that it aims to support psychedelic experiential opportunities for practitioners that will be part of a Phase 1 clinical study. During our conversation, we asked Payton Nyquvest about Numinus’ ability to administer MDMA assisted therapy if it receives FDA approval before the announced trial with MAPS is complete. We also discussed whether this partnership marks a new progressive chapter in deepening ties and building a stronger relationship with MAPS. Most importantly, we asked whether these partnerships are exclusive.
That’s not all the news from Numinus, however, that Nyquvest has to share. There’s a new Chief Financial Officer who has been hired, and this development dovetails with a very exciting possibility of a NASDAQ that might be coming this fall. Find out why this CFO hire is so important to the company in the face of becoming publicly traded.
Listen in to get the latest.